Whyte Michael P, Madson Katherine L, Mumm Steven, McAlister William H, Novack Deborah V, Blair Jo C, Helliwell Timothy R, Stolina Marina, Abernethy Laurence J, Shaw Nicholas J
Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children, St. Louis, MO, USA; Division of Bone and Mineral Diseases, Washington University School of Medicine at Barnes-Jewish Hospital, St. Louis, MO, USA.
J Bone Miner Res. 2014 Dec;29(12):2601-9. doi: 10.1002/jbmr.2289.
Among the high bone mass disorders, the osteopetroses reflect osteoclast failure that prevents skeletal resorption and turnover, leading to reduced bone growth and modeling and characteristic histopathological and radiographic findings. We report an 11-year-old boy with a new syndrome that radiographically mimics osteopetrosis (OPT), but features rapid skeletal turnover. He presented at age 21 months with a parasellar, osteoclast-rich giant cell granuloma. Radiographs showed a dense skull, generalized osteosclerosis and cortical thickening, medullary cavity narrowing, and diminished modeling of tubular bones. His serum alkaline phosphatase was >5000 IU/L (normal <850 IU/L). After partial resection, the granuloma re-grew but then regressed and stabilized during 3 years of uncomplicated pamidronate treatment. His hyperphosphatasemia transiently diminished, but all bone turnover markers, especially those of apposition, remained elevated. Two years after pamidronate therapy stopped, bone mineral density (BMD) Z-scores reached +9.1 and +5.8 in the lumbar spine and hip, respectively, and iliac crest histopathology confirmed rapid bone remodeling. Serum multiplex biomarker profiling was striking for low sclerostin. Mutation analysis was negative for activation of lipoprotein receptor-related protein 4 (LRP4), LRP5, or TGFβ1, and for defective sclerostin (SOST), osteoprotegerin (OPG), RANKL, RANK, SQSTM1, or sFRP1. Microarray showed no notable copy number variation. Studies of his nonconsanguineous parents were unremarkable. The etiology and pathogenesis of this unique syndrome are unknown.
在高骨量疾病中,骨质石化症反映了破骨细胞功能衰竭,这会阻止骨骼的吸收和更新,导致骨生长和塑形减少,并出现特征性的组织病理学和影像学表现。我们报告了一名11岁男孩,患有一种新的综合征,其影像学表现类似于骨质石化症(OPT),但具有快速的骨骼更新特征。他在21个月大时出现了鞍旁富含破骨细胞的巨细胞肉芽肿。X线片显示颅骨致密、全身骨质硬化和皮质增厚、髓腔变窄以及管状骨塑形减少。他的血清碱性磷酸酶>5000 IU/L(正常<850 IU/L)。部分切除后,肉芽肿复发,但在3年的帕米膦酸治疗无并发症期间逐渐消退并稳定。他的高磷酸酶血症暂时减轻,但所有骨转换标志物,尤其是那些与骨沉积相关的标志物,仍然升高。帕米膦酸治疗停止两年后,腰椎和髋部的骨密度(BMD)Z值分别达到+9.1和+5.8,髂嵴组织病理学证实骨重塑迅速。血清多重生物标志物分析显示硬化蛋白水平较低。脂蛋白受体相关蛋白4(LRP4)、LRP5或转化生长因子β1(TGFβ1)的激活,以及硬化蛋白(SOST)、骨保护素(OPG)、核因子κB受体活化因子配体(RANKL)、核因子κB受体活化因子(RANK)、p62/sequestosome-1(SQSTM1)或分泌型卷曲相关蛋白1(sFRP1)缺陷的突变分析均为阴性。基因芯片显示无明显的拷贝数变异。对他非近亲结婚的父母的研究未发现异常。这种独特综合征的病因和发病机制尚不清楚。